Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension
Aim. To provide a pharmacoeconomic estimate of macitentan versus bosentan in therapy for pulmonary arterial hypertension (PAH). Subject and methods. An analysis was carried out on the basis of a social perspective for patients, whose mean age was 50 years. A budget impact analysis was performed with...
Main Authors: | O M Moisseeva, A V Rudakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2017-03-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/32213/pdf |
Similar Items
-
Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
by: Abdullah M. Aldalaan, et al.
Published: (2022-04-01) -
Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
by: Jie Li, et al.
Published: (2022-12-01) -
Pulmonary hypertension: reasonable selection of specific therapy
by: N A Karoli, et al.
Published: (2018-03-01) -
The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
by: S N Avdeev
Published: (2016-07-01) -
A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
by: N A Tsareva, et al.
Published: (2017-09-01)